ERBB2 and breast cancer: Similarly, a Korean study linked HER2-low with better breast cancer-specific survival (BCSS) (HR = 0.68; 95% CI = 0.49–0.93; and p=0.019) and improved 5-year DFS rates (76.4% vs. 65.5%, p=0.026) [36].